key: cord-0782659-ft8g1wf5 authors: Psichogiou, M.; Karabinis, A.; Poulakou, G.; Antoniadou, A.; Kotanidou, A.; Degiannis, D.; Pavlopoulou, I. D.; Chaidaroglou, A.; Roussos, S.; Mastrogianni, E.; Eliadi, I.; Basoulis, D.; Petsios, K.; Leontis, K.; Kakkalou, E.; Protopapas, K.; Jahaj, E.; Pratikaki, M.; Syrigos, K. N.; Lagiou, P.; Gogas, H.; Tsiodras, S.; Magiorkinis, G.; Paraskevis, D.; Sypsa, V.; Hatzakis, A. title: COMPARATIVE IMMUNOGENICITY OF BNT162b2 mRNA VACCINE WITH NATURAL COVID-19 INFECTION date: 2021-06-21 journal: nan DOI: 10.1101/2021.06.15.21258669 sha: 69e6ccb8405c1230ace3ecc1cf80cc3aabde2584 doc_id: 782659 cord_uid: ft8g1wf5 The mRNA vaccine BNT162b2 has proven highly effective and currently many millions are being vaccinated. There are limited and conflicting data from immunogenicity studies on the effects of age, gender, vaccination side effects (VSE), risk factors for severe COVID-19 (RFS-COV), obesity (BMI) and previous SARS-CoV-2 (Pr-CoV) Moreover, immunogenicity data from COVID-19 patients comparing various disease categories of natural infection i.e. asymptomatic vs mild vs moderate vs severe infection are sparse, and include limited number of individuals. This study included 871 vaccinated health care workers (HCW) and 181 patients with natural infection. Immunogenicity was assessed by a quantative assay measuring anti-SARS-CoV-2 against the RBD domain of the spike protein (anti-RBD) and anti-SARS-CoV-2 against nucleocapsid protein (anti-N). Samples were collected 1-2 weeks after completion of the 2nd dose in the vaccinated HCWs and 15-59 days post symptoms onset in patients with natural infection. The concentration of anti-RBD in vaccinated individuals after multivariable analysis was significantly associated with age, gender, VSE and Pr-CoV. Specifically, anti-RBD median levels (95% CI) were lower by 2,466 (651-5,583), 6,228 (3,254-9,203) and 7,651 (4,479-10,823) AU/ml in 35-44, 45-54, 55-70 yrs respectively, compared with 18-34 yrs group. In females, median levels of anti-RBD were higher by 2,823 (859-4,787) compared with males, in individuals with VSE were higher by 5,024 (3,122-6,926) compared with no VSE, and in HCWs with Pr-CoV were higher by 9,971 (5,158-14,783) AU/ml compared with HCWs without Pr-CoV. Among individuals with natural infection, the median anti-RBD levels were 14.8 times higher in patients with critical COVID-19 infection compared with non-hospitalized individuals. The ratio of anti-RBD in vaccinated individuals versus those with natural infection varied from 1.0 up to 19.4 according to the clinical subgroup of natural infection. This study proves the high immunogenicity of BNT162b2 vaccine although its sustainability remains to be seen. The use of comparative data from natural infection serological panels, expressing the clinical heterogeneity of natural infection may facilitate early decisions for vaccine evaluation in clinical trials. Coronavirus disease 2019 (COVID-19) is expanding despite mitigation policies of variable success. By the end of 2020, an increasing number of safe and effective vaccines were approved, and large vaccination programs are underway around the world. By May 15, 2021 more than 162,500,000 cases and 3,371,000 deaths were reported while more than 1.41 billion vaccine doses were administered. The first approved vaccine was Pfizer -BNT162b2, a lipid nanoparticle -formulated mRNA vaccine encoding the SARS-CoV-2 full length spike modified by two proline mutations. Preliminary findings among healthy men and women showed that two 30mg doses elicited high SARS-CoV-2 neutralizing antibody titers and robust antigen-specific CD8+ and Th1-type CD4+ T-cell responses [1] . Moreover, in a multinational, placebo -controlled observer blinded efficacy trial including 43.548 healthy or with stable chronic conditions participants, the vaccine was found safe with an efficacy of 95% (95% credible interval 90.3-97.6%) in preventing symptomatic COVID-19 disease ≥7 days after the 2nd dose [2] . Similar vaccine efficacy (90-100%) was observed across groups defined by age, sex, race, baseline body mass index (BMI) and the presence of coexisting conditions. History of previous COVID-19 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 21, 2021. ; https://doi.org/10.1101/2021.06.15.21258669 doi: medRxiv preprint treatment, immunosuppressive therapy or diagnosis with an immunocompromising condition were exclusion criteria in this pivotal study. A second approved mRNA vaccine, Moderna -mRNA 1273, showed similar efficacy 94.1% (95% 89.3 -96.8) in preventing COVID-19 illness [3] . The BNT162b2 was also evaluated in a mass vaccination campaign in Israel with an efficacy, 7 days from the 2nd dose, of 94%, 87% and 92% in preventing symptomatic disease, hospitalization, and severe disease, respectively [4] . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Herein, we report comparative immunogenicity data of BNT162b2 mRNA vaccine after the 2 nd dose with a large cohort of individuals with natural COVID-19 infection. Participants were vaccinated with 2 doses of BNT162b2 21 days apart. The vaccine was administered intramuscularly and included 30 mg of SARS-CoV-2 full length lipid nanoparticle formulated mRNA. The study was designed to assess immunogenicity at time intervals 1-2 weeks after the 2 nd dose (28-35 days) and 4, 6, 8, and 12 months after the 1 st dose. Immunogenicity 1-2 weeks after the 2 nd dose was expected to be highest, based on the results from phase I/II studies [1]. HCWs from 2 teaching hospitals, Laiko General Hospital (Hospital 1) and Onassis Cardiac Surgery Center (Hospital 2) were informed about the study and participated after signing an informed consent. A brief questionnaire was administered to HCWs with information about age, gender, education, position within hospital, BMI, history of risk factors for severe COVID-19 (RFS-CoV), previous COVID-19 (Pr-CoV) and history of adverse reactions after vaccination (VSE). A group of 315 patients with natural SARS-CoV-2 infection diagnosed with RT-PCR testing was included in the study. Participants provided informed consent. Age, gender, diagnostic All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Serum samples collected after venipuncture, were tested for SARS-CoV-2 IgG binding antibodies to nucleocapsid protein (anti-N) and anti-SARS-CoV-2 receptor binding domain (RBD) spike protein IgG (anti-RBD). The second assay (Abbott SARS-CoV-2 IgG II Quant) or anti-RBD was used to quantify IgG antibodies against the receptor binding domain (RBD) of the S1 subunit of the spike protein. The linear range is between 21 and 40,000 AU/ml. The lower limit of detection was 6.8 AU/ml and the reportable interval 6.8-80,000 AU/ml. Both assays are based on chemiluminescent microparticle immune assay (CLIA). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Median values, 25th and 75th percentiles were used to describe anti-RBD levels. We Eight hundred seventy-one HCWs participated in the study. Their sociodemographic characteristics are shown in Table 1a . The prevalence of the SARS-CoV-2 anti-N IgG was 3.7% (32 out of 871) (95% CI 2.5-5.2%) and of the anti-RBD IgG was 99.7% (868 out of 871) (95% CI 99.0-99.3%). The concentrations of anti-RBD ranged from <6.8 up to higher than 80.000 AU/ml. The 2.5 th , 50 th and 97.5 th percentiles of anti-RBD were 1,680, 15,877 and 55,309 AU/ml, respectively (Supp. Figure 1) . The median (IQR) anti-RBD levels by age, gender, country of birth, BMI, risk factors for severe COVID-19, side effects of vaccination and previous SARS-CoV-2 infection are shown in Table All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. for COVID-19 showed statistically significant association with concentrations of anti-RBD. However, in a multivariable linear regression analysis only gender, age, side effects of vaccination and previous SARS-CoV-2 infection, showed statistically significant associations with concentrations of anti-RBD (Table 2 ). More specifically, females had on average 2,823 (95% CI 859-4,787) AU/ml concentration higher than males HCWs (p = 0.05). Participants aged 55-70 yrs had on average 7,651 (95% CI 4,479-10,823) AU/ml lower than HCWs 1834 yrs (p<0.001). HCWs reporting side effects had a concentration of 5,024 (95% CI 3,122-6,926) AU/ml higher than those non-reporting side effects (p<0.001). Moreover, HCWs with previous SARS-CoV-2 had higher levels by 9,971 (95% 5,158-14,783) AU/ml compared to COVID-19 naïve individuals (p<0.001). Time from 2 nd dose: The median levels of anti-RBD were calculated according to the time from the 2 nd dose. The maximum levels were reached 11 days after the 2 nd dose while a sharp reduction was observed 15-17 days after the 2 nd dose (Kruskal-Wallis, p=0.007) (Suppl. Table 1 ). Multivariable analysis showed that reduction was independent of age, gender, side effects of vaccination and previous SARS-CoV-2 infection (data not shown). The early convalescent samples post-symptoms onset (PSO) ≥15-59 days of symptomatic (n=155), asymptomatic individuals (n=9), hospitalized (n=157) and non-hospitalized (n=23) individuals were included in this analysis. The sociodemographic and clinical characteristics are shown in Table 1b . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The prevalence (95% CI) of anti-N and anti-RBD was 88.3% (82.7-92.6%) and 90.6% (85.3-94.4%) respectively. The median (IQR) anti-RBD levels by age, gender, symptomatic/asymptomatic, severity of clinical disease and time POS are shown in Table 3 . The median (IQR) anti-RBD concentrations were 9 (<6.8-520) and 5,547 (1,415-13,325) AU/ml in asymptomatic and symptomatic individuals respectively (p<0.001), 6,271 (1,583-14,121) and 808 (9-1,668) hospitalized and non-hospitalized respectively. The median (IQR) anti-RBD levels were highly associated with increased severity; Mild: 1,634 (751-7,868), Moderate: 6,082 (2,433-12,224), Severe: 6,638 (3,053-13,837) and Critical 11,975 (5,138-23,351) AU/ml (p<0.001 for between group comparisons). Hospitalized individuals had 7.8-fold times higher median anti-RBD levels than nonhospitalized. Specifically, patients with moderate, severe and critical disease had 4.0, 4.4, 7.9fold times higher anti-RBD level, than those with asymptomatic/mild infection, respectively The ratio of median anti-RBD levels in vaccinated after the 2 nd dose versus the median levels of those with natural infection in the early convalescent period 15-59 days POS is shown in We observed several fold differences in the anti-RBD ratio for each vaccinated group e.g., across different age groups, i.e., 18-34, 35-44, 45-54, 55-70 years old, and the ratio of median anti-RBD levels for vaccinated over natural infection was 1.9-15.4, 1.6-13.0, 1.2-9.8 and 1.0-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 21, 2021. ; https://doi.org/10.1101/2021.06.15.21258669 doi: medRxiv preprint 7.9, respectively. In the group with VSE the ratio was 1.6-12.7 and in the group with Pr-CoV 2.4-19.4 (Figure 2 ). For the whole group of vaccinated individuals, the ratio was 1.3, 2.5, 10.5 based on critical, moderate/severe and asymptomatic/mild patients with natural infection respectively. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The present analysis assumes according to findings from previous reports that NA and anti-RBD are correlates of protection against SARS-CoV-2. Although the mechanism of protection is complex including several aspects of humoral and cell-mediated immunity, the role of neutralizing antibodies seems profound. The use of multiple NA assays, many of them requiring increased biosafety laboratories is a barrier for large clinical studies. The use of anti-RBD or other antibodies against spike protein may accelerate the study of pathogenesis of SARS-CoV-2 and provide useful tools for assessing vaccine efficacy and their effectiveness All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This study has some strengths including the large number of vaccinated individuals evaluated, the use of a large natural infection panel and the use of a validated, commercially available assay for anti-RBD testing. The major limitation is the lack of cell-mediated immunity tests to capture aspects of T and B cell immunity. Prospective evaluation of vaccine immunogenicity in large, vaccinated cohorts is underway and the comparison, with prospective data from natural infection may clarify important questions of COVID-19 pathogenesis and vaccine effectiveness over time. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 21, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 21, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 21, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. anti-RDB (AU/ml) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 21, 2021. ; https://doi.org/10.1101/2021.06.15.21258669 doi: medRxiv preprint BNT162b2 induces SARS-CoV-2-neutralising antibodies and poly-specific T cells in humans. U Sahin Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity Antibody response to SARS-CoV-2 infection in humans: A systematic review Neutralizing antibody titres in SARS-CoV-2 infections Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study SARS-CoV-2 infection rates of antibody-positive compared with antibodynegative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) Kinetics of antibody responses dictate COVID-19 outcome Supplementary Table 1. Median (25 th -75 th ) levels of anti-SARS-CoV-2 RBD IgG by time (days) from 2 nd dose of BNT162b2 vaccine Ν (%) Median Abbreviations: 25th-75th, 25th and 75th percentiles AU/ml, arbitrary units per milliliter